On the Wednesday, January 28, 2026, episode of The Excerpt podcast: As GLP-1 use surges, lawsuits allege blindness, stomach paralysis and more. USA TODAY Investigative Reporter Austin Fast breaks down ...

X is putting its money where its mouth is. The Elon Musk-owned social media platform just pledged it will give $1 million to the user who creates the most popular long-form post using its newly ...

Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...

On Thursday, OpenAI announced its investment in neurotech startup Merge Labs, cofounded by its CEO, billionaire Sam Altman. OpenAI will collaborate with the new venture to develop technology to link ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

The icon, who has cowritten a new book on obesity, tells PEOPLE she 'tried to beat the medication' Jamie Green In 2023, Oprah Winfrey revealed that she was taking GLP-1 weight loss medication, telling ...

OpenAI CEO Sam Altman’s new brain-computer interface startup, Merge Labs, is being spun out of the Los Angeles–based nonprofit Forest Neurotech, according to a source with direct knowledge of the ...

GLP-1 usage is on the rise, and researchers are looking for other health benefits associated with the drug, including its effects on bladder health. But as GLP-1s rise in popularity, so do nicknames ...

Lando Norris winning the F1 drivers' championship in Abu Dhabi Clive Rose / Getty Images Just a day after winning his first Formula One world championship, Lando Norris faced a big decision for the ...

CLEVELAND, Ohio — One in eight adults in the United States are now using Ozempic, Wegovy or similar GLP-1 drugs, according to a new KFF Health Tracking Poll. The poll also found that cost and side ...

Dec 1 (Reuters) - The World Health Organization on Monday issued its first guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment for the ...

Compared with unexposed pregnancies, the GLP-1 RA-exposed group had a higher risk for preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy. HealthDay News — Glucagon-like ...